Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Applied DNA Sciences Inc APDN

Technology Scientific & Technical Instruments
Applied DNA Sciences, Inc. is a biotechnology company that develops, and markets deoxyribonucleic acid (DNA) based technology solutions. The Company is utilizing its LinearDNA large-scale polymerase chain reaction (PCR) based manufacturing platform. The Company’s proprietary platform produces large quantities of DNA for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic... see more

Recent & Breaking News (NDAQ:APDN)

Applied DNA Submits PCR-based Monkeypox Virus Diagnostic Test for Approval to New York State Department of Health

Business Wire August 19, 2022

Applied DNA Reports Third Quarter Fiscal 2022 Financial Results

Business Wire August 11, 2022

Applied DNA Biotherapeutics Subsidiary Reports LinearDNA(TM) Platform Development Milestone: First Successful Administration of LinearDNA In Vivo via Lipid Nanoparticles (LNP)

Business Wire August 10, 2022

Applied DNA Awarded Extension of Health Services Contract with The City University of New York 

Business Wire August 9, 2022

Applied DNA Receives Approximately $3.6 Million in Net Proceeds from Warrant Exercise

Business Wire August 9, 2022

Applied DNA to Host Conference Call and Webcast Discussing Fiscal 2022 Third Quarter Results and Corporate Updates

Business Wire August 8, 2022

Applied DNA Announces Closing of Upsized $12 Million Public Offering

Business Wire August 8, 2022

Applied DNA Announces Pricing of $12 Million Upsized Public Offering, Priced at a Premium to Market Under Nasdaq Rules

Business Wire August 4, 2022

Applied DNA Initiates Analytical Validation of PCR-based Diagnostic Test Specific to Monkeypox Virus

Business Wire August 2, 2022

Applied DNA Biotherapeutics Subsidiary LineaRx and EvviVax Publish Additional Positive Animal Proof-of-Concept Data Supporting LinearDNA(TM) Platform as a Unique Approach to Veterinary DNA Vaccine Development

Business Wire July 25, 2022

Applied DNA Biotherapeutics Subsidiary LineaRx to Present Data Showcasing Advantages of its Enzymatically Produced LinearDNA as Substitute for Plasmid DNA in IVT mRNA Production at the 2nd Annual mRNA-Based Therapeutics Summit

Business Wire July 22, 2022

Applied DNA Launches Initiatives to Expand Awareness of LinearDNA(TM) Platform as an Alternative to Plasmid DNA for Therapeutic Applications, Revamps LineaRx Website  

Business Wire June 29, 2022

U.S. Government Guidance Permits DNA Traceability and Isotopic Testing as Evidence under Uyghur Forced Labor Prevention Act

Business Wire June 21, 2022

Applied DNA and EvviVax Announce Peer-Reviewed Publication of Positive Preclinical Data for LinearDNA(TM) Platform as a Novel Cancer Vaccine Strategy in the Journal of Experimental & Clinical Cancer Research

Business Wire June 6, 2022

Applied DNA Reports Second Quarter Fiscal 2022 Financial Results

Business Wire May 12, 2022

Applied DNA Schedules Fiscal 2022 Second Quarter Financial Results Conference Call and Webcast for Thursday, May 12, 2022

Business Wire May 9, 2022

Applied DNA Awarded NYC-Based 'Return-to-Office'

Business Wire April 6, 2022

Applied DNA to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT

Business Wire March 23, 2022

Applied DNA Executes LOI with Spindle Biotech for Research Collaboration on Simplified High Yield mRNA Production System

Business Wire March 14, 2022

Applied DNA to Participate in Fireside Chat at the 34th Annual ROTH Investor Conference

Business Wire March 10, 2022